Cancer of the urological system commonly occurs in the kidney,bladder,and prostate gland.The clear cell subtype of renal cell carcinoma(ccRCC)constitutes the great majority of kidney cancer.Metastatic ccRCC portends a...Cancer of the urological system commonly occurs in the kidney,bladder,and prostate gland.The clear cell subtype of renal cell carcinoma(ccRCC)constitutes the great majority of kidney cancer.Metastatic ccRCC portends a very poor outcome with no effective treatment available.Prostate cancer is the most common cancer in males in the US.Despite recent advances in selective kinase inhibitors and immunotherapies,the rate of developing new treatment from bench to bedside is slow.A time-consuming step is at the animal drug testing stage,in which the mouse model is the gold standard.In the pursuit to streamline the in vivo cancer biology research and drug development,we explored the feasibility of the chicken chorioallantoic membrane(CAM)model to establish xenografts.The CAM model greatly shortens the time of tumor growth and lowers the cost comparing to immunocompromised mice.We generated CAM xenografts from ccRCC,bladder and prostate cancer,with established cancer cell lines and freshly isolated patient-derived tissues,either as primary tumor cells or small pieces of tumors.The successful CAM engraftment rate from the different tumor sources is 70%or above.Using our previously established metastatic ccRCC mouse model,we showed that the CAM xenograft maintains the same tumor growth pattern and metastatic behavior as observed in mice.Taken together,CAM can serve as a valuable platform to establish new patient-derived xenografts(PDXs)to study tumor biology,thus accelerating the development of individualized treatment to halt the deadly metastatic stage of cancer.展开更多
基金This study was supported by National Cancer Institute/-National Institutes of Health(Grant No.1R21CA216770)UC Tobacco-related Disease Research Program(Grant No.27IR-0016),Department of Defense(Grant No.W81XWH-15-1-0256)Cancer Research Coordinating Committee(Grant No.CRC15-380768)to L.W.UCLA institutional support grant support included:UCLA JCCC grant no.P30CA016042,and UCLA CTSI grant no.UL1TR001881(to L.W.).We thank UCLA Translational Pathology Core Laboratory for the preparation of tumor samples.
文摘Cancer of the urological system commonly occurs in the kidney,bladder,and prostate gland.The clear cell subtype of renal cell carcinoma(ccRCC)constitutes the great majority of kidney cancer.Metastatic ccRCC portends a very poor outcome with no effective treatment available.Prostate cancer is the most common cancer in males in the US.Despite recent advances in selective kinase inhibitors and immunotherapies,the rate of developing new treatment from bench to bedside is slow.A time-consuming step is at the animal drug testing stage,in which the mouse model is the gold standard.In the pursuit to streamline the in vivo cancer biology research and drug development,we explored the feasibility of the chicken chorioallantoic membrane(CAM)model to establish xenografts.The CAM model greatly shortens the time of tumor growth and lowers the cost comparing to immunocompromised mice.We generated CAM xenografts from ccRCC,bladder and prostate cancer,with established cancer cell lines and freshly isolated patient-derived tissues,either as primary tumor cells or small pieces of tumors.The successful CAM engraftment rate from the different tumor sources is 70%or above.Using our previously established metastatic ccRCC mouse model,we showed that the CAM xenograft maintains the same tumor growth pattern and metastatic behavior as observed in mice.Taken together,CAM can serve as a valuable platform to establish new patient-derived xenografts(PDXs)to study tumor biology,thus accelerating the development of individualized treatment to halt the deadly metastatic stage of cancer.
